Yvan Malepart, President and CEO Macopharma
Watch the videoSubscribe via email
THERAFLEX UV-Platelets will make a significant contribution to public health and will give patients peace of mind… At the same time, it will offer a very cost-effective solution for healthcare providers.”
YM: “THERAFLEX UV-Platelets will be an important part of our future and will complement our existing range of blood processing, biotherapy and hospital products in a very impactful way. In the world of blood transfusion, it is a revolution in the production of platelet concentrates. As the only technology to provide inactivation without the use of a reagent, it is a game-changer.”
YM: “We expect it to have a major impact in multiple regions around the world. Given the increasing number of emerging pathogens, we expect health authorities to move to pathogen inactivation – rather than testing or screening – for their blood products.